IRVINE, Calif.--(EON: Enhanced Online News)--Khang & Khang LLP (the “Firm”) announces that it is investigating claims against Novocure Limited. (“Novocure Limited” or the “Company”) (Nasdaq: NVCR) concerning possible violations of federal securities laws.
“[w]hile barriers to full adoption remain, I am optimistic we will overcome the challenges inherent in bringing a completely new therapy into widespread clinical use.”
If you purchased shares of Novocure Limited. and want more information free of charge, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at firstname.lastname@example.org.
Novocure designs and sells treatment for solid tumor cancers therapy referred to as the tumor treating fields (“TTFields”). Novocure markets its proprietary therapy, TTFields delivery system, through the Optune name as a monotherapy treatment for adult patients with glioblastoma brain cancer.
Novocure disclosed that its new Optune prescriptions fell to 657 in the second quarter from 755 in the first. Asaf Danziger, Chief Executive Officer of Novocure, stated “[w]hile barriers to full adoption remain, I am optimistic we will overcome the challenges inherent in bringing a completely new therapy into widespread clinical use.”
When this news was disclosed to the public, Novocure’s stock dropped in value, causing investors severe harm.
If you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at email@example.com.
This press release may constitute Attorney Advertising in some jurisdictions.